Is Psychedelic Therapy Ready for FDA Approval?

Why It Matters

Regulatory clearance hinges on rigorous, context‑controlled trials, determining whether psychedelics become a mainstream, investable treatment option.

Key Takeaways

• Psychedelic therapy hinges on drug‑induced plasticity plus therapeutic context.
• FDA denied MDMA PTSD trial, causing market valuation drop.
• Small, under‑powered studies dominate; larger phase‑2/3 trials emerging.
• Set and setting, including music, critically influence outcomes.
• Therapist bias and recovered‑memory risks demand rigorous quality control.

Summary

The conversation with UCSF neuroscientist Robin Carhart‑Harris examines whether psychedelic‑assisted therapies are poised for FDA approval. He frames the treatment as a combination of a drug that opens a "plastic" mental state and a carefully managed therapeutic context that must shape that plasticity.

Carhart‑Harris describes a field that rode a hype wave after Michael Pollan’s bestseller, then suffered a market correction when MAPS’s MDMA‑for‑PTSD application was rejected. Despite the setback, publication rates have surged, with dozens of small trials and a handful of larger phase‑2/3 studies—most notably Compass Pathways’ psilocybin program for treatment‑resistant depression—pushing the evidence base toward regulatory readiness.

Key examples illustrate the nuance: he likens music to a "hidden therapist," and stresses that set (mindset) and setting (environment) are integral to outcomes. He also recounts a troubling case where a therapist’s strong belief in recovered memories may have steered a patient’s experience, underscoring the need for strict therapist training and bias mitigation.

The implications are clear: FDA approval will depend not only on drug safety and efficacy data but also on standardized, high‑quality therapeutic protocols. Investors, clinicians, and policymakers must watch how the industry addresses context control and ethical safeguards, as these factors will shape the next wave of psychedelic medicine commercialization.

Original Description

Sam Harris speaks with Robin Carhart-Harris about psychedelic research and its therapeutic potential. They discuss the current state of the field, the FDA denial of MDMA-assisted therapy for PTSD, the critical role of set and setting, risks for vulnerable populations, the REBUS model of how psychedelics work on the brain, the default mode network and ego dissolution, microdosing, the neuroscience of consciousness, DMT entities, and other topics.

Dr Carhart-Harris moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol. He has designed human brain imaging studies with LSD, psilocybin, MDMA, and DMT, and several clinical trials of psilocybin therapy for severe mental illnesses, including 3 key trials in depression plus 2 further trials in anorexia and fibromyalgia syndrome. Dr Carhart-Harris founded the Centre for Psychedelic Research at Imperial College London in April 2019, the first of its kind in the world. In 2020, he was named among the top 31 medical scientists by The Times newspaper. Dr Carhart-Harris became the inaugural Ralph Metzner Distinguished Professor of Neurology and Psychiatry at the University of California, San Francisco in 2021, and in the same year, was listed in TIME magazine’s ‘100 Next’ - a list of emerging leaders from around the world who are shaping the future.

Website: carhartharrislab.com

SUBSCRIBE to gain access to all full-length episodes of the podcast at https://samharris.org/subscribe/ OR become a channel member to access episodes on YouTube. For those who can't afford the full subscription price, we offer partial scholarships https://www.samharris.org/subscribe/scholarship

Stay updated on new episodes, essays, and events — subscribe to Sam Harris’s free newsletter: https://samharris.org/newsletter-signup/